文献速递帕金森病与运动障碍

非洲及非洲混合人群帕金森病遗传风险位点鉴定与因果洞察:一项全基因组关联研究

Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study.
PubMed 文献 · Lancet Neurol · 2023-08-23

该研究在非洲及非洲混合血统人群中开展全基因组关联研究,纳入197918人(1488例病例和196430例对照),在GBA1基因座rs3115534-G发现新的帕金森病常见风险因素(总荟萃分析OR 1.58,95%CI 1.37-1.80,p=2.397×10⁻¹⁴),并关联发病年龄。该信号在非非洲人群中罕见,似与葡萄糖脑苷脂酶活性降低相关。

要点

  • 在GBA1基因座rs3115534-G发现新的帕金森病风险因素,总荟萃分析OR 1.58(95%CI 1.37-1.80)。
  • 该变异与非洲血统发病年龄相关(β=-2.00,SE=0.57,p=0.0005)及非洲混合血统(β=-4.15,SE=0.58,p=0.015)。
  • 该变异在非非洲人群中罕见,本研究评估的病例中39%存在该变异。

核心结论

  • 研究在非洲血统人群中鉴定出GBA1基因座新的遗传风险因素,该因素在欧洲人群中未见,可能是非洲人群帕金森病的主要机制基础。
  • 该人群特异性变异相比全基因组关联研究识别的常见变异对帕金森病施加相当风险,在本研究评估的病例中39%存在该变异。

研究设计与样本

  • 全基因组关联研究,纳入来自全球帕金森遗传学项目、国际帕金森病基因组学联盟非洲部和23andMe的多个队列。
  • 共纳入197918人(1488例病例和196430例对照);除23andMe为基于临床诊断的自我报告外,每个队列中每例个体的帕金森病诊断均由运动障碍专科医生临床确认。

主要发现

  • 在GBA1基因座rs3115534-G发现新的帕金森病常见风险因素(总荟萃分析OR 1.58,95%CI 1.37-1.80,p=2.397×10⁻¹⁴)。
  • 该变异与发病年龄相关:非洲血统β=-2.00(SE=0.57,p=0.0005),非洲混合血统β=-4.15(SE=0.58,p=0.015)。
  • 该变异在非非洲或非非洲混合人群中罕见。
  • 下游短读长和长读长全基因组测序分析未揭示全基因组关联研究信号下的编码或结构变异。
  • 所识别的信号似乎与葡萄糖脑苷脂酶活性降低相关。

关键数值与推荐

  • 总荟萃分析帕金森病风险OR 1.58(95%CI 1.37-1.80),p=2.397×10⁻¹⁴。
  • 非洲血统发病年龄β=-2.00(SE=0.57),p=0.0005;非洲混合血统β=-4.15(SE=0.58),p=0.015。
  • 本研究评估的病例中39%存在该变异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 23andMe队列中帕金森病诊断基于临床诊断的自我报告,而非运动障碍专科医生临床确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An understanding of the genetic mechanisms underlying diseases in ancestrally diverse populations is an important step towards development of targeted treatments. Research in African and African admixed populations can enable mapping of complex traits, because of their genetic diversity, extensive population substructure, and distinct linkage disequilibrium patterns. We aimed to do a comprehensive genome-wide assessment in African and African admixed individuals to better understand the genetic architecture of Parkinson's disease in these underserved populations. METHODS: We performed a genome-wide association study (GWAS) in people of African and African admixed ancestry with and without Parkinson's disease. Individuals were included from several cohorts that were available as a part of the Global Parkinson's Genetics Program, the International Parkinson's Disease Genomics Consortium Africa, and 23andMe. A diagnosis of Parkinson's disease was confirmed clinically by a movement disorder specialist for every individual in each cohort, except for 23andMe, in which it was self-reported based on clinical diagnosis. We characterised ancestry-specific risk, differential haplotype structure and admixture, coding and structural genetic variation, and enzymatic activity. FINDINGS: We included 197 918 individuals (1488 cases and 196 430 controls) in our genome-wide analysis. We identified a novel common risk factor for Parkinson's disease (overall meta-analysis odds ratio for risk of Parkinson's disease 1·58 [95% CI 1·37-1·80], p=2·397 × 10-14) and age at onset at the GBA1 locus, rs3115534-G (age at onset β=-2·00 [SE=0·57], p=0·0005, for African ancestry; and β=-4·15 [0·58], p=0·015, for African admixed ancestry), which was rare in non-African or non-African admixed populations. Downstream short-read and long-read whole-genome sequencing analyses did not reveal any coding or structural variant underlying the GWAS signal. The identified signal seems to be associated with decreased glucocerebrosidase activity. INTERPRETATION: Our study identified a novel genetic risk factor in GBA1 in people of African ancestry, which has not been seen in European populations, and it could be a major mechanistic basis of Parkinson's disease in African populations. This population-specific variant exerts substantial risk on Parkinson's disease as compared with common variation identified through GWAS and it was found to be present in 39% of the cases assessed in this study. This finding highlights the importance of understanding ancestry-specific genetic risk in complex diseases, a particularly crucial point as the Parkinson's disease field moves towards targeted treatments in clinical trials. The distinctive genetics of African populations highlights the need for equitable inclusion of ancestrally diverse groups in future trials, which will be a valuable step towards gaining insights into novel genetic determinants underlying the causes of Parkinson's disease. This finding opens new avenues towards RNA-based and other therapeutic strategies aimed at reducing lifetime risk of Parkinson's disease. FUNDING: The Global Parkinson's Genetics Program, which is funded by the Aligning Science Across Parkinson's initiative, and The Michael J Fox Foundation for Parkinson's Research.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Rizig M, Bandres-Ciga S, Makarious MB, et al. Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study. Lancet Neurol. 2023. PMID: 37633302. doi:10.1016/S1474-4422(23)00283-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。